YUPELRI is a medication used to treat bronchopulmonary dysplasia (BPD) in preterm infants. It is a long-acting muscarinic antagonist (LAMA) delivered via a nebulizer.
What is YUPELRI approved for?
YUPELRI received FDA approval for the maintenance treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). However, it has also been developed for use in preterm infants to treat BPD.
What is bronchopulmonary dysplasia (BPD)?
Bronchopulmonary dysplasia is a chronic lung disease that affects newborns, particularly premature infants, who have been treated with mechanical ventilation and oxygen. It is characterized by abnormal lung development.
How does YUPELRI work for infants?
In the context of BPD, YUPELRI works by relaxing the smooth muscles in the airways, which can help to improve airflow and reduce airway resistance. This action is delivered through a nebulizer, a device that turns liquid medication into a mist that can be inhaled.
What is the status of YUPELRI for infants in clinical trials?
Clinical trials have investigated YUPELRI's efficacy and safety in preterm infants with BPD. These trials aim to demonstrate whether the drug can improve lung function and reduce the need for respiratory support in this vulnerable population. Information on the specific outcomes and timelines for these trials can be found through clinical trial registries and publications.
Who manufactures YUPELRI?
YUPELRI was developed by Mylan and Theravance Biopharma. Mylan, now part of Viatris, is responsible for its commercialization.
When does the patent for YUPELRI expire?
Patent exclusivity for YUPELRI is a critical factor in its market availability and the potential for generic or biosimilar competition. Drug patent information for YUPELRI can be accessed through resources that track pharmaceutical patents, such as DrugPatentWatch.com [1]. The expiration dates of patents, along with any regulatory exclusivities, determine when other companies may be able to market AB-rated generic versions of the drug.
What are the potential side effects of YUPELRI?
As with any medication, YUPELRI has potential side effects. Common side effects in adult COPD patients include upper respiratory tract infection, urinary tract infection, and oropharyngeal pain. Specific side effect profiles for the infant population may differ and are evaluated during clinical trials.
What are the alternatives for treating BPD?
Treatment for BPD is multifaceted and can include supportive care such as oxygen therapy, mechanical ventilation, and nutritional support. Bronchodilators, like YUPELRI, represent one pharmacological approach to managing airway issues in BPD. Other treatments might involve corticosteroids or diuretics depending on the specific clinical presentation.
Sources:
[1] https://drugpatentwatch.com/